Skip to content
Open access

A multi-omics computational framework identifies cell-type-specific therapeutic targets and active compounds of Tripterygium wilfordii Hook.f. against diabetic kidney disease.

Oct 2026 · Computational biology and chemistry · Vol 126 Pt 2, pp. 109511 · 0 citations · 56 references
Medicine

Abstract

Diabetic kidney disease (DKD) is a leading cause of chronic and end-stage kidney disease, and current therapies leave patients at high risk. Tripterygium wilfordii Hook.f. (TWHF), a traditional Chinese medicine, reduces proteinuria in DKD, but the compounds and molecular targets responsible remain poorly defined. We hypothesized that specific bioactive compounds of TWHF ameliorate DKD through interactions with cell-type-specific molecular targets, thereby modulating inflammatory, immune, and tissue-remodeling pathways involved in disease progression. By integrating transcriptomic analysis, immune-infiltration profiling, single-cell RNA sequencing, virtual gene knockout analysis, and molecular docking, this study developed a comprehensive computational framework to investigate the cell-type-specific and multi-target mechanisms of TWHF in DKD. Using the GEO study GSE30529 (with 22 microdissected human kidney samples), we intersected predicted TWHF targets with DKD-associated and differentially expressed genes from human kidney tubules, and identified four key genes (CCR2, MMP7, PLK2, and PSMB9) that were upregulated in DKD and negatively correlated with glomerular filtration rate. The immune microenvironment in diseased kidneys was found to be remodelled based on an immune-infiltration analysis. Single-cell analysis localized MMP7 to loop-of-Henle epithelial cells, CCR2 to leukocyte, and PLK2 and PSMB9 to endothelial cells, and these genes were implicated in epithelial remodeling and endothelial dysfunction based on virtual gene knockout analysis. Furthermore, molecular docking predicted interactions between the four key proteins and three hub TWHF compounds, with triptolide showing the strongest predicted affinity. In an independent triptolide-response dataset generated from A549 cells, triptolide produced a dose- and time-dependent reduction in PLK2 expression. Collectively, CCR2, MMP7, PLK2, and PSMB9 were identified to be candidate therapeutic targets and Triptolide as a leading active compound, with the potential triptolide-PLK2 regulatory relationship should be further investigated. These results support our hypothesis that TWHF acts through direct, multi-compound engagement of multiple cell-type-specific targets, pointing to a multi-target, multi-pathway mechanism for TWHF in DKD and providing a mechanistic framework for subsequent experimental validation.

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.